Cantor Fitzgerald Forecasts Sanara MedTech FY2025 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Sanara MedTech in a report released on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($2.43) for the year, down from their prior estimate of ($0.98). Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The business had revenue of $26.31 million for the quarter, compared to analyst estimates of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Separately, HC Wainwright lifted their price target on shares of Sanara MedTech from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday.

Sanara MedTech Stock Up 5.4 %

Shares of NASDAQ SMTI opened at $31.22 on Friday. Sanara MedTech has a 1 year low of $26.00 and a 1 year high of $39.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The firm has a market cap of $272.89 million, a PE ratio of -31.54 and a beta of 1.37. The company has a 50 day simple moving average of $34.31 and a 200 day simple moving average of $33.77.

Institutional Trading of Sanara MedTech

Several institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its position in shares of Sanara MedTech by 0.9% in the 4th quarter. Northern Trust Corp now owns 40,816 shares of the company’s stock worth $1,355,000 after purchasing an additional 358 shares during the period. Wells Fargo & Company MN lifted its holdings in Sanara MedTech by 53.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,893 shares of the company’s stock valued at $63,000 after buying an additional 663 shares during the period. Barclays PLC boosted its position in Sanara MedTech by 12.1% during the fourth quarter. Barclays PLC now owns 6,423 shares of the company’s stock valued at $213,000 after acquiring an additional 692 shares during the last quarter. Bank of America Corp DE boosted its position in Sanara MedTech by 38.7% during the fourth quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock valued at $125,000 after acquiring an additional 1,055 shares during the last quarter. Finally, Squarepoint Ops LLC grew its holdings in Sanara MedTech by 9.6% during the 4th quarter. Squarepoint Ops LLC now owns 14,822 shares of the company’s stock worth $492,000 after acquiring an additional 1,294 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.